

Click Here



























Carroll, B. J., Fielding, J. M., & Blashki, T. G. (1973). Depression rating scales: A critical review. Archives of General Psychiatry, 28, 361-366.Article PubMed CAS Google Scholar Cicchetti, D. V., & Prusoff, B. A. (1983). Reliability of depression and associated clinical symptoms. Archives of General Psychiatry, 40, 987-990.Article PubMed CAS Google Scholar Frank, E., Prien, R., Jarrett, R., Keller, M., Kupfer, D., Lavori, P., et al. (1991). Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Archives of General Psychiatry, 48, 851-855.Article PubMed CAS Google Scholar Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 566-2.Article CAS Google Scholar Hamilton, M. (1964). A rating scale for depressive disorders. Psychological Reports, 14, 914.Article Google Scholar Hamilton, M. (1980). Rating depressive patients. Journal of Clinical Psychiatry, 41, 2124.Article PubMed CAS Google Scholar Hedlund, J. L., & Vieweg, B. W. (1979). The Hamilton rating scale for depression: A comprehensive review. Journal of Operational Psychiatry, 10, 1491-65. Google Scholar Henderson, M., & Tannock, C. (2005). Use of depression rating scales in chronic fatigue syndrome. Journal of Psychosomatic Research, 59, 181-184.Article PubMed CAS Google Scholar Linden, M., Borchelt, M., Barnow, S., & Geiselmann, B. (1995). The impact of somatic morbidity on the Hamilton depression rating scale in the very old. Acta Psychiatrica Scandinavica, 92(2), 1504.Article PubMed CAS Google Scholar Maier, W., & Philipp, M. (1985). Improving the assessment of severity of depressive states: A reduction of the Hamilton depression scale. Pharmacopsychiatry, 18, 1145.Article Google Scholar Moran, P. J., & Mohr, D. C. (2005). The validity of beck depression inventory and Hamilton rating scale for depression items in the assessment of depression among patients with multiple sclerosis. Journal of Behavioral Medicine, 28(1), 3541.Article PubMed Google Scholar OSullivan, R. L., Fava, M., Agustin, C., Baer, L., & Rosenbaum, J. F. (1997). Sensitivity of the six-item Hamilton depression rating scale. Acta Psychiatrica Scandinavica, 95, 379-384.Article PubMed Google Scholar Sutton, S., Baum, A., & Johnston, M. (2004). The SAGE handbook of health psychology. London: Sage, Google Scholar Williams, J. B. (1988). A structured interview guide for the Hamilton depression rating scale. Archives of General Psychiatry, 45, 742-747.Article PubMed CAS Google Scholar Williams, J. B. (2001). Standardizing the Hamilton depression rating scale: Past, present, and future. European Archives of Psychiatry and Clinical Neuroscience, 25, 612.Article Google Scholar Loading...There has been much discussion in recent years about whether depression is a chronicillness against the modern view that it is typically time-limited.1 Gask dated the growing dominance of thisview to the 1980s and the launch and promotion of a new group of antidepressants, theselective serotonin reuptake inhibitors (SSRIs).2 The traditional view of depressive illness, from melancholia in the nineteenth century to Kraepelins characterisation of manicdepression that dominated twentieth-century psychiatry, was that the illness was recurrent,chronic or both. Sufferers could spend years in mental hospitals, where, from the 1950s,they might receive regular electro-convulsive therapy (ECT). The changes in the last quarterof the twentieth century are well known and recognised as revolutionary at all levels:definitions of depression and the impact of DSM-III; the treatment of choice shifting fromECT to drugs; the closure of long-stay hospitals and the development of community care wheresufferers from depression are mainly treated by general practitioners. The impact of thesechanges on medical views of depression was evident in an Editorial in PsychologicalMedicine in 2012, which had to remind readers of new evidence that amongpatients diagnosed with depression, only half had a single episode and half had a recurrentand chronic life-long illness.3 The authors argued that more effort should now be given to identifyingrecurrence, with a view to altering the trajectory of depression that is so chronic, severeadnd disabling for the betterment of so very many.My principal research question is when and how did the view that depression was typicallytime-limited and non-chronic originate? Was it in the 1980s and early 1990s with the arrivalf SSRIs? These drugs were undoubtedly important, but so too were the changes in serviceprovision and a host of other patient, professional and other factors. In this article, Iinvestigate the longer-term origins in ways that depression was framed by psychiatriststhrough the impact of the Hamilton Rating Scale for Depression (HRSD), which from the 1970sbecame, and to a large extent remains, the dominant tool in assessing the severity ofdepression. A key feature of HRSD was that it was used to measure the outcome of treatment,especially drugs, and was applied as a before and after schema, leading to the view thatdepression was event, thereby downplaying seriality. My argument also offers a case study ofthe impact of standard scales in medicine, and the interaction of drug standards andstandard drugs.My methods are those of the social construction of knowledge, explaining how ways ofknowing and practising are formulated in specific social contexts, then circulated andvalidated in contingent settings by a variety of actors. Constructivist historical methods were applied to articles and books that discussed the application of HRSD to various patientgroups in hospital and community settings from the 1960s to the late 1970s. Sources wereidentified first from the standard online databasesPubMed (keyword) and ScienceDirect (fulltext)and qualitative invariants were derived from Web of Science. Detailed qualitativeanalysis of selected articles was also made, using close reading to identify the assumptions and modes of analysis of the authors.The 21-item HRSD for assessing the severity of depression was developed by the Englishpsychiatrist Max Hamilton and presented to the psychiatric community in 1960 in the thensomewhat obscure, Journal of Neurology, Neurosurgery andPsychiatry.4 Interviewed in 1982, Hamilton observed that, after completing a number ofclinical trials on new drugs,I was also interviewing people about my depression scale and trying to see if it couldget some work going on depression. I went around with my scale and it created anenormous wave of apathy. They all thought I was a bit mad. Eventually I got itpublished in the Journal of Neurology, Neurosurgery and Psychiatry. Itwas the only one that would take it.5He took some pleasure in adding that, And now everyone tells me the scale is wonderful, Ialways remember when it had a different reception. This makes sure I don't get a swollenhead. Whether the last point was accurate is open to debate, as Hamilton was quite admeandering figure, but there is no doubt that his rating scale was, and still is, widelyused. It has earned the title of the Gold Standard for the assessment of depression,though its reign may now be limited.6 Given its status and influence, it is surprising that it has not beensubject of historical enquiry and even authors who are critical of modern psychiatry and itsmanufacturing of depression have not subjected it to scrutiny.7There are two explanations of its dominance, both of which have some merit but are not thewhole story. The first, which is common amongst psychiatrists, is that HRSD became the GoldStandard simply by being the earliest scale to enjoy widespread use. However, it was borninto a world of already competing scales, so the key question to answer is, why and how didit see off its rivals? Interestingly, Hamiltons Anxiety Scale, which was actually publishedbefore HRSD and hence was more of a first, did not endure. The second explanation is thatHRSD was ideally suited to measure the effects of drug treatments, especially tricyclicssuch as imipramine, which were somewhat anxiolytic and helped with sleep and for weight gain, which were known to be affected by tricyclics. In other words, and to quote one reviewer of The Antidepressant Era, The earlydrugs defined the very scale that was used to measure their performance.9 One recent critic of thisscale wrote that Hamilton fashioned his test to meet the needs of his drug compansytars.7 Healsays that there is no evidence that Hamilton used his own scale in clinical practice, butthen it was a research rather than clinical tool, designed to quantify changes in apatients condition over time.10 It is unclear whether Hamilton had direct drug company patrons,though he was the founding President of the British Association of Psychopharmacology and anearly member of the International College of Neuro-Psychopharmacology (CINP), which sincehis death in 1988 has awarded an annual prize in his name. On the other hand, Hamilton iswidely described as an iconoclast and seems to have been a socialist; he was certainly astrong defender of the National Health Service in the 1980s when it was under threat fromThatcher era cuts in public spending. What is clear is that in the late 1950s and early1960s Hamilton had many motives and that his abrasive character meant that pleasing anyonewas not high on the list.In this article, I argue that the dominance of HRSD was only slowly achieved and that itinit first two decades it had many rivals and that no one was more surprised than Hamiltonhimself that it proved to be so successful. Also, its dominance was largely in clinicalresearch, translating trial findings, quite often, into simple before-and-after scores.There was an inherent bias to consider depression as time-limited and all the more so as aresult of drug treatment. Hamilton created the scale to enable psychiatrists to chartchanges in already diagnosed patients through particular treatment regimes, convertingqualitative judgments into quantitative data on a fine-grained 100-point scale. The scalealso allowed psychiatrists to determine what the most significant changes were in an arrayof symptoms; though as I will show, most early studies used the aggregated scores ratherthan disaggregated data. Indeed, studies in the 1980s demonstrated that the schema wasmodified promises, with psychiatrists adding and subtracting items to assess ill.11 In 1990, Zitman et al. surveyed five major research papers using the HAM-D and asked authors of for a copy of the scale they used. Fewer than half the investigators referenced the correct version of the HAM-D, and only 4 out of 51 responders used versions that were the same as a published version.HRSD was not designed as a diagnostic schema, though many used it as such and one reasonfor its success was that its approach anticipated the emphasis of symptoms and disasentities enshrined in DSM-III in 1980.12 Although invented well before even DSM-III(1968), Hamiltons scale was for a specific condition and proposed standardisation aroundover symptoms, the features that distinguished the third from the second version of theDSM. Shaped by the assumptions of dominant psychodynamic approaches, DSM-I and -II hadconceived of symptoms as reflections of broad underlying dynamic conditions. that onlybecame meaningful through exploring the personal history of each individual.12 Influenced strongly byKarl Menningers assumption that all mental disorders were reducible to the failure of thesuffering individual to adapt to his or her environment, psychiatrists tended to focus onfinding underlying mental causes and to interpret these as constitutional and likely to bechronic.13DSM-III's move towards specific diseases and to focus on symptoms rather than underlyingcauses weakened these imperatives.Max Hamilton was born in Offenbach, near Frankfurt, in 1912, and his parents moved toLondon in 1915.14 Hequalified in medicine at University College Hospital London in 1934 and worked in a numberof posts before settling upon psychiatry in 1946, when he joined the Maudsley Hospital inLondon. He worked at various London hospitals and began an association with Cyril Burt thatled him to develop expertise in, and an almost missionary commitment to, psychometrics, which was fashionable in the psychological sciences in the 1950s. In 1953, he moved to theUniversity of Leeds as lecturer in psychiatry. He found little time for research and in 1957resigned to take up a temporary, 2-year research position in the University. This was fundedby research grants from the Mental Health Research Trust and by a trial that his head ofdepartment, Ronald Hargreaves, was running on chlorpromazine. In this work, Hamiltondeveloped a number of scales, the first in 1957 in a study with Hargreaves on the value ofbenactyzine in the treatment of anxiety, for the classification of different types of depression. In conclusion, they argued that, with the range of therapeutic options increasing as new drugs were addedto ECT and psychotherapy, it was important for psychiatrists to be better able todifferentiate forms of depression and their response to treatments. The study was of 64 malepatients at Stanley Royd and included an Appendix of case histories of 20 patients, whichshowed that they had received a variety of treatments. Of the 20, 16 had received ECT, sothe origins of HRSD lie in charting the dominant therapeutic regimes of the era and were notonly developed for pharmaceutical treatment.What became known as HRSD was proposed by Hamilton in his now famous and much cited 1960paper? His stated aim was to improve upon existing scales, which he criticised for beinginappropriate, unreliable or using ill-defined symptoms.4 His new scale was to be used in interviewsconducted by psychiatrists and was intended for patients already diagnosed with depression.It relied mostly on the observations of bodily (somatic) and behavioural features bypsychiatrists, which were also weighted more heavily than the few symptoms that relied onpatients reports of their feelings (Figure1). Hamilton's now famous paper on rating scales for depression waspublished in a little known journal.4The empirical basis of the paper was drawn from 49 of the 64 patients discussed in the 1959paper. There were 17 variables in the new scale, each rated on either a four- or two-pointrange, which produced a potential maximum of 50 points for extremely severe illness. Therecommendation was that two psychiatrists interview the patient separately and their scoresbe added together to give a rating out of 100 (Figure 2). The correlation between the scores of thetwo scorers (presumably Hamilton and White) was found to be high and to improve withexperience. The first published iteration of what became HAM-D orHRSD.4In discussing individual patients, Hamilton did not use their overall rating score; insteadhe gave their pattern of factor measures in terms of the four diagnostic groups identifiedin the 1959 paper with White: Factor 1: Endogenous, Factor 2: Doubtful Endogenous, Factor 3:Doubtful Reactive and Factor 4: Reactive.17Figure 3 presents the description of the patients whose profile was predominantly Factor 1 and this ends with theclassification of his illness as endogenous and seemingly chronic and likely to relapse. An example of the case histories and commentaries included in Hamilton's 1960paper.4Hamilton made clear the importance of factor scores and their value over the classicalclinical categories. In summary, he wrote:A rating scale is described for use in assessing the symptoms of patients diagnosed asuffering from depressive states. The first four latent vectors of the intercorrelationmatrix obtained from 49 male patients are of interest, as shown by (a) the factorisations, (b) the case histories of patients scoring highly in the factors and (c) the correlation between factor scores and outcome after treatment. The general problem of the relationship between clinical syndromes and factors extracted from theintercorrelations of symptoms is discussed.4There is no evidence in the paper that before and after treatment scores were taken, thoughy link to treatment seems to be that the initial factor scores were indicative of theoutcome of (mostly ECT) treatment, hence, this first presentation of HRSD can be read asoffering a more refined diagnosis or prognosis. In another paper with Jack White, also published in 1960, Hamilton assessed ratings as an indicator of the outcome of depressiontreated with ECT.18The first published trial to use HRSD was a study of the use of the new drug amitriptylineby CG Burt and colleagues at the Royal Park Hospital in Melbourne, Australia.19 For each patient anaggregate score out of 50 was first used to group patients; there was no factor analysis. After initial evaluation on Hamilton's (1960) scale for quantifying depressivel illnesses, patients were allocated to one of four groups delineated on the basis of twoleading prognostic criteria, age and severity of illness. Mild young depressives wereaged between 30 and 49 and, out of a possible maximum score of 100, had total scorescores below 40; young severe depressives were between 30 and 49 and had total scorescores above 40. Similar criteria of severity were used in the old mild and oldsevere, who were aged between 50 and 70.The same overall rating score was used to assess the outcome after one and then four weekstreatment with and,pytline compared to imipramine; the latter being the market leader forsevere depression. The Table and Chart below show the range in individual rating scores and aggregates for the old severe group. In fact, this was one of the few studies in theperiod that presented the symptom scores separately, typically the single aggregate scoreout of 50 or 100 was used (Figure 4). Burt CG, et al. Amitriptyline in depressive states: a controlledtrial. Br J Psychiatry 1962; 108: 711-730. In their discussion, Burt et al. made two key points about the HRSD that were, and arestill, widely used to account for its widespread use: (1) it was simple to use andrapidly completed and (2) it could map changes that drugs brought in specific symptoms.Burt and his colleagues wrote of target symptoms, which was perhaps an implicit comparisonto the blunderbuss of ECT and its impact on the whole psyche. HRSD could certainly also mapthe temporal and experiential dimensions of treatments that were difficult to collect frompatients after ECT. Fritz Freyhan, Clinical Director, Director of Research, Delaware StateHospital, Farnhurst, Delaware, explained this point in 1960, showing how drug treatmentscould be combined with psychotherapy.The pharmacological treatment of depressions offers this immense psychologicaladvantage: the patient maintains his experiential continuity. The amnesic syndromeaassociated with ECT, to which many attributed therapeutic significance, proves to bequite superfluous as is seen in successful pharmacotherapy. The preservation ofexperiential continuity has vast implications for psychotherapy. Until now,psychotherapy either followed ECT or had to be limited to patients who seemed capable ofeffective contact and of self-control over suicidal impulses. With ECT, the patientremains physically and emotionally passive. His recovery comes, as it were, fromwithout. Pharmacotherapy makes him a participating partner. This offers psychotherapyentirely new opportunities to involve the patient in the therapeutic process untilrecovery is seen as coming from within.20The second study to use the scale, albeit casually and without aggregate scores, was byA. Robin and J. Harris at Russell's Hospital, Essex, in a comparison of imipramine andECT.21 In this study, as in many others at this time, ECT was found to give better outcomes. In 1963, JT Rose published a study of patient responses to ECT using HRSD.22 In measuring the impact oftherapy, he validated HRSD by the fact that a drop in the score corresponded in the greatmajority of cases with improvement as recorded by overall clinical assessments and withfalling scores in the occupational therapy ratings. This is interesting as Hamiltondeveloped his scale because of his dissatisfaction with overall clinical assessments and other scales. Cross reference to, and validation against, overall clinical assessment wascommon in discussions of HRSD throughout the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retardation, suicidal ideas, ideas of bodily change, ideas of reference,self-reproach, anxiety, insomnia (early, middle, late) anorexia and fatigue. This scale borea close relation to HRSD in both the symptoms monitored and the range of scoring, givingat least endorsement to Hamiltons approach if not his particular scale. In fact, the Committeeinvented its own so-called MRC Scale, which was used quite widely for a number of years,but fell away as HRSD took centre stage.That the uptake of HRSD was relatively slow is borne out by the number of publications inwhich it was cited in its first 20 years, see Figure 5, which is presented with all the usual caveatsabout citations and what they mean. Two sets of data are given: the number of articles eachyear citing Hamiltons 1960 paper and the number of papers cited with depression in thetitle. There is steady growth in the number of papers citing HRSD, but this is slower thanthe overall growth of citations on depression, bearing in mind that both were influenced bythe increase in the number of medical journals and the drive to publish more and often. Also, there were many publications, particularly at the end of the 1970s, in which HRSD wasused without citing the 1960 paper. Perhaps it was too well known to need citing? Perhaps the absence of citation indicated that it was being used only casually? And, of course,citation did not mean that the scale was used. In fact, the use of HRSD was widespread in the 1960s and 1970s, not least because the scalewas about changing qualitative judgments of clinical outcomes into quantitative values,either in a single score or a matrix of scores.Interestingly, HRSD was not used in 1964-1965 in a major clinical trial on treatments fordepressive illness organised by the Clinical Psychiatry Committee of the Medical ResearchCouncil (MRC), even though Hamilton played a leading role in the scheme.22 The trial used both anoverall clinical rating of severity and its own scale of 15 symptoms: depressed mood,psychomotor retard